Wedge Therapeutics

Executive Summary

Wedge Therapeutics is a preclinical-stage biotechnology company based in Cambridge, Massachusetts, developing a proprietary mandibular thrust oral airway device for medical use, with a stated focus on oncology. Founded in 2018, the company operates at the intersection of medical devices and small molecule therapeutics, though its primary disclosed technology is a non-invasive airway management tool. The company has not yet reported any funding rounds, pipeline candidates, or clinical development milestones, and its website provides limited details on specific therapeutic applications. Given its early stage and lack of public data, Wedge Therapeutics represents a high-risk opportunity with no near-term catalysts. The company's potential value lies in the differentiated design of its oral airway device, which may address unmet needs in emergency or perioperative airway management, particularly in cancer patients with compromised airways. However, without any disclosed preclinical or clinical data, the technology's feasibility and market potential remain unvalidated.

Upcoming Catalysts (preview)

• TBDFirst Public Funding or Partnership Announcement20% success
• TBDRegulatory Clearance (FDA 510(k)) for Airway Device10% success